Altre lingue Invites Biocore Co., Ltd.

Azioni

A216400

KR7216400002

Prezzo di chiusura Korea S.E. Altri mercati azionari 00:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
9.060 ^KRW	-0,98%		-5,53%	-2,58%

2022

Invites Biocore Co., Ltd. (XKON:A216400) ha completato l'acquisizione dell'85% della partecipazione in PROCAGEN da Byun Seok-soo.

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

CrystalGenomics Invites Co., LTD. agreed to acquire an 89.95% stake in PROCAGEN from Invites Biocore Co., Ltd. and others for KRW 13.1 billion	28/12
Invites Healthcare Co., Ltd. agreed to acquire Invites Genomics Co., Ltd. from Invites Biocore Co., Ltd. for KRW 10 billion	17/05/23
Invites Biocore Co., Ltd. completed the acquisition of 85% stake in PROCAGEN from Byun Seok-soo.	15/07/22
Invites Biocore Co., Ltd. agreed to acquire 85% stake in PROCAGEN from Byun Seok-soo.	14/07/22
Biocore Co., Ltd. announced that it has received KRW 41.999997 billion in funding	31/03/21
Biocore Co., Ltd. announced that it expects to receive KRW 41.999997 billion in funding	17/02/21
BioCore Inc. Signs Agreement with Osprey Medical, Inc	25/11/20
Biocore Co., Ltd. announced that it has received KRW 7.99999527 billion in funding	08/07/20
Invites Healthcare Co., Ltd. agreed to acquire a 20.03% stake in Biocore Co., Ltd. from Hongkong Dian Biotechnology Co., Limited for KRW 12 billion.	01/07/20
Biocore Co., Ltd. announced that it expects to receive KRW 7.99999527 billion in funding	30/06/20
Biocore Co., Ltd. announced that it expects to receive KRW 5.04114275 billion in funding	01/10/19
K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1, MAVI New Growth Good Corporation Investment Fund No. 2 acquired 2.67% stake in Biocore Co., Ltd. from Kwanghyun Lee and Seunghyun Lee for KRW 2.1 billion.	02/08/16
Kiwoom Securities Co., Ltd. acquired approximately 1.8% stake in Biocore Co., Ltd. from SCL Healthcare Co., Ltd. and Kyungryul Lee for approximately KRW 1.6 billion.	02/08/16
IBKC-SBI Bio Fund 1 of SBI Investment Korea Co., Ltd., MAGNA Investment Co., Ltd., MGI Secondary Fund 1 of MG Investment Co., Ltd. and SEMA-InterVest Bio Healthcare Fund of InterVest Co., Ltd. acquired additional 5.56% stake in Biocore Co., Ltd. from Lee, Kyungryul for KRW 4.9 billion.	02/08/16
SBI Investment Korea Co., Ltd. through its SBI-Growth Ladder KONEX Vitalization Fund acquired 2.3% stake in Biocore Co., Ltd. from Kyungryul Lee for KRW 1.9 billion.	29/07/16
Moon-Kyu Gong acquired 1.22% stake in Biocore Co., Ltd. from Jeong-Woo Lee for KRW 700 million.	27/10/15
K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1 and MAVI New Growth Good Corporation Investment Fund No. 2 acquired 8.88% stake in Biocore Co., Ltd. from Kwang-Hyun Lee and Seung-Hyun Lee for KRW 4 billion.	27/10/15
Biocore Co., Ltd. completed the acquisition of Cytogenetic and Human Genome division of Seoul Clinical Laboratories.	21/10/15
Biocore Co., Ltd. agreed to acquire Cytogenetic and Human Genome division of Seoul Clinical Laboratories for KRW 2.9 billion.	18/08/15
Intelsius Announces Partnership with Biocore Co. Ltd. in South Korea	27/03/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Invites Biocore Co., Ltd.

Azioni

A216400

KR7216400002

Altre lingue

Filtri